Language
繁体
Caretarge
Yuanqi Hesheng uses Chlamydomonas reinhardtii (Chlamydomonas reinhardtii)
Express the chassis for a brand new look
Establish an efficient expression system for recombinant protein drugs in microalgae cells
Especially the synthesis and development of complex structural proteins
Yuanqi Hesheng is committed to functional recombinant proteins
Build a chassis based on Rhein Chlamydomonas reinhardtii
Functional protein CDMO platform
Advantages of the product
Natural safety
Chlamydomonas reinhardtii is a natural edible alga for human beings. Due to its special structural cells, rapid growth, clear genetic background and easy transformation, it has become an emerging model species for studying gene function, foreign gene expression and biological hydrogen production. It is called "green yeast" and "photosynthetic yeast". In 2019 and 2022, it has been recognized and approved by the US Food and Drug Administration and the China's National Health Commission of China for direct consumption, and its metabolites do not contain toxic substances such as endotoxin.
active protein
Chlamydomonas reinhardtii has unique evolutionary characteristics that are shared by both animals and plants. It possesses various post-translational modifications of proteins, resulting in recombinant protein products with background source activity. The genetic operation system of Chlamydomonas reinhardtii cells is perfect, which can efficiently screen recombinant protein drugs.
Targeted precision
The Yuanqi Hesheng team obtained highly efficient expression of recombinant hirudin in Chlamydomonas reinhardtii cell lines through large-scale screening, and demonstrated from a biochemical perspective that sulfation modification of the 63rd tyrosine residue of the recombinant hirudin protein from Chlamydomonas reinhardtii can effectively help inhibit thrombin, reduce total cholesterol, triglycerides, and other conditions.
About Us
The core team of the company gathers scientists and bioengineers from top universities such as Tsinghua University. It is a globally leading research team that develops complex structural proteins based on Chlamydomonas reinhardtii. With 14 years of experience in Chlamydomonas reinhardtii and related technologies, it has solid professional knowledge and rich practical experience in key fields such as bioinformatics, gene editing, and AI algorithms.
Yuanqi Hesheng uses Chlamydomonas reinhardtii as a new expression platform, dedicated to the synthesis and development of functional recombinant proteins, especially complex structural proteins.
At the beginning of its launch, Yuanqi Hesheng established a grand vision of "redefining the future of life sciences with 'Double D technology' (DNA+DATA)".
Yuan Qihesheng is researching 12 development pipelines: recombinant hirudin, development of anti obesity and type II diabetes drugs (GLP-1 and its analogues), formation of egg yolks (BMP2, BMP7, etc.), lactoferrin and other recombinant proteins. Yuanqi Biotechnology will efficiently and intelligently create a functional protein CDMO based on Chlamydomonas reinhardtii as the chassis.
Yuanqi Hesheng uses Chlamydomonas reinhardtii as a new expression platform, dedicated to the synthesis and development of functional recombinant proteins, especially complex structural proteins.
At the beginning of its launch, Yuanqi Hesheng established a grand vision of "redefining the future of life sciences with 'Double D technology' (DNA+DATA)".
Yuan Qihesheng is researching 12 development pipelines: recombinant hirudin, development of anti obesity and type II diabetes drugs (GLP-1 and its analogues), formation of egg yolks (BMP2, BMP7, etc.), lactoferrin and other recombinant proteins. Yuanqi Biotechnology will efficiently and intelligently create a functional protein CDMO based on Chlamydomonas reinhardtii as the chassis.
Collaborative partners
